TransCode Therapeutics (RNAZ) Announces 1:28 Reverse Share Split

Go back to TransCode Therapeutics (RNAZ) Announces 1:28 Reverse Share Split

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split

May 2, 2025 4:10 PM UTC

Split designed to achieve compliance with Nasdaq minimum bid price requirements

BOSTON, May 2, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved a 1-for-28 reverse stock split. The reverse stock split was approved by TransCode's stockholders on May 2, 2025, and is intended to increase the per... More